CHAPTER 12. Peritoneal Dialysis
|
|
- Randall Nicholson
- 6 years ago
- Views:
Transcription
1 23rd Report of the PERITONEAL DIALYSIS CHAPTER 12 Peritoneal Dialysis Sunita Bavanandan Anita Bhajan Manocha Lily Mushahar Mohamad Zaimi Bin Abdul Wahab
2 PERITONEAL DIALYSIS 23rd Report of the SECTION 12.1: Modali es and Prescrip on of PD (Tables ) In 2015, there are 4315 pa ents on peritoneal dialysis (PD) in Malaysia this represents a growth of 16.5 from the preceding year and 178 over the last decade. The bulk of PD therapy remains in the form of CAPD (82.9) with no growth in the propor on on APD (13.2) and a declining number on DAPD (3.9 versus 5.2) (Table ). It would be interes ng to see if this trend is related to increasing use of Icodextrin in long overnight dwells but that data is not presently captured. Table : Peritoneal dialysis regimes, PD regime n n n n n Standard CAPD DAPD Automated PD/ CCPD Total PD regime n n n n n Standard CAPD DAPD Automated PD/ CCPD Total In 2015, 65.5 of pa ents were on the Baxter disconnect system and 34 on the Fresenius disconnect system (Table ). The majority of pa ents on CAPD (90.3) are using 4 exchanges a day. Fewer pa ents compared to previous years are performing 5 exchanges a day. This may reflect a lower threshold to convert pa ents requiring be er clearances to haemodialysis (Table a). The majority (83) of pa ents on APD use 10L total volume exchanges daily but there are 6.2 using 8L exchanges and 8.1 using >10L exchanges daily (Table bi). For CAPD, 87.6 of pa ents in 2015 are using 8L total volume exchanges, while 9 use 10L exchanges daily. Table : CAPD connectology, CAPD connectology n n n n n CAPD Baxter disconnect Fresenius disconnect Others Unknown APD Baxter disconnect Fresenius disconnect Others Unknown
3 23rd Report of the PERITONEAL DIALYSIS Table : CAPD connectology, ( cont) CAPD connectology n n n n n CAPD Baxter disconnect Fresenius disconnect Others Unknown APD Baxter disconnect Fresenius disconnect Others Unknown Table a: CAPD Number of Exchanges per day, Number of exchanges/ day n n n n n Unknown Total Number of exchanges/ day n n n n n Unknown Total Table bi: APD total dwell volumes per day, Total dwell volumes/ day n n n n n Unknown Total
4 PERITONEAL DIALYSIS 23rd Report of the Table bi: APD total dwell volumes per day, ( cont) Total dwell volumes/ day n n n n n Unknown Total Table bii: CAPD total dwell volumes per day, Total dwell volumes/ day n n n n n Unknown Total Total dwell volumes/ day n n n n n Unknown Total In 2015, the number of pa ents doing self-care CAPD was 63 whereas this propor on was only 32 in APD. This indicates that the requirement for assistance (coupled with access to?nancing) is the main determinants for the choice of APD rather than correla on with membrane status. Table : Assistance to Perform PD, PD regime/assistance n n n n n CAPD Self-care Par al self-care Completely assisted Unknown Automated PD Self-care Par al self-care Completely assisted Unknown
5 23rd Report of the PERITONEAL DIALYSIS Table : Assistance to Perform PD, ( cont) PD regime/assistance n n n n n CAPD Self-care Par al self-care Completely assisted Unknown Automated PD Self-care Par al self-care Completely assisted Unknown Figure (a): Assistance to Perform CAPD, Figure (b): Assistance to Perform APD, Self-care completely assisted Partial Self-care Unknown Self-care completely assisted Partial Self-care Unknown Percent () Percent () CAPD APD SECTION 12.2: ACHIEVEMENT OF SOLUTE CLEARANCE AND PERITONEAL TRANSPORT The percentage of pa ents achieving target solute clearance of 1.7 per week has been declining over the last decade (Table ). This trend may be due to a change in the recommended target Kt/V on PD adequacy in 2007 and highlights the need to actually target a higher Kt/V to achieve the minimum requirement in solute clearance. There is a 1.6-fold inter-centre varia on in the propor on of pa ents achieving the delivered Kt/V in 2015 (55 in 5th percen le and 89 in 95th percen le). This wide inter-centre varia on has been present every year (Table ). The majority of incident PD pa ents have either low average or high average membrane transport status (Table ). However, there was a shi to high average and high transport status over me (Table ). Table and Figure shows the decline in residual renal volume (RRV) over me although up to 50 of PD pa ents have urine output above 400 mls un l 4 years on PD. 171
6 PERITONEAL DIALYSIS 23rd Report of the Table : Distribu on of delivered Kt/V, PD pa ents Year Number of pa ents Mean SD Median LQ UQ pa ents 1.7 per week Figure : Cumula ve distribu on of delivered Kt/V, PD pa ents Figure : Varia on in propor on of pa ents with Kt/V 1.7 per week among PD centres with KT/V >=1.7 per week (lower 95 CI, upper 95 CI) 80 Cumulative distribution patients KT/V Centre Table : Varia on in propor on of pa ents with Kt/V 1.7 per week among PD centres, Year Number of centre Min 5 th Cen le Median LQ UQ 95 th Cen le Max 172
7 23rd Report of the PERITONEAL DIALYSIS Table : Peritoneal transport status by PET D/P crea nine at 4 hours, new PD pa ents Year n n n n n Low Low average High average High Total Year n n n n n Low Low average High average High Total Table : Peritoneal Transport Status (PET) with dialysis vintage Dura on (Years) <1 1-<2 2-<3 3-<4 4-<5 n n n n n Low Low average High average High Total Dura on (Years) 5-<6 6-<7 7-<8 8-<9 9-<10 10 or more n n n n n n Low Low average High average High Total Table : Residual Urine Volume Dura on (Years) <1 1-<2 2-<4 4 or more n n n n <100 ml <400 ml <800 ml <1000 ml >=1000 ml Total
8 PERITONEAL DIALYSIS 23rd Report of the Figure : Residual Urine Volume in prevalent PD pa ents (2015) 100 <100 mls 100-<400 mls 400-<800 mls 800-<1000 mls >=1000 mls 80 Percent () <1 1-<2 2-<4 >=4 Duration(Years) SECTION 12.3: TECHNIQUE SURVIVAL ON PD Table and Figure a & b show pa ent technique survival by era. Technique survival was be er in the first 4 years in the recent era () compared to when censored for death and transplant. In, technique survival was 93, 79 and 72 at 1, 3 and 4 years respec vely. Younger age group (age <14 years) had be er technique survival in the first 5 years (censored for death and transplant) compared to older age group (Table & Figure b) but a er 5 years on treatment, age 65 years had be er technique survival compared to younger age group (Table & Figure b). Tables and Figures (a) & (b) show those of female gender consistently had be er technique survival than their male counterparts. Table (a): Unadjusted technique survival by era and (uncensored for death and transplant) Era Interval (month) n Survival SE n Survival SE
9 23rd Report of the Figure a: Unadjusted technique survival by era and (uncensored for death and transplant) PERITONEAL DIALYSIS Figure (b): Unadjusted technique survival by era and (censored for death and transplant) 1.00 Kaplan-Meier survival estimates, by Era 1.00 Kaplan-Meier survival estimates, by Era Cumulative survival Year Year Cumulative survival Year Year Duration in months Duration in months Table (b): Unadjusted technique survival by era and (censored for death and transplant) Era Interval (month) n Survival SE n Survival SE Table (a): Unadjusted technique survival by age (uncensored for death and transplant) Age group (years) <= Interval (month) n Survival SE n Survival SE n Survival SE n Survival SE 175
10 PERITONEAL DIALYSIS 23rd Report of the Table (a): Unadjusted technique survival by age (uncensored for death and transplant) ( cont) Age group (years) Interval (month) n >=65 Survival SE n Survival SE n Survival SE Figure (a): Unadjusted technique survival by age (uncensored for death and transplant) Kaplan-Meier survival estimates, by Age Figure (b): Unadjusted technique survival by age (censored for death and transplant) Kaplan-Meier survival estimates, by Age Age 1-14 Cumulative survival Age Age Age Age 1-14 Age>=65 Age Age Cumulative survival Age Age Age Age>=65 Age Age Duration in months Duration in months 176
11 23rd Report of the PERITONEAL DIALYSIS Table (b): Unadjusted technique survival by age (censored for death and transplant) Age group (years) Interval (month) n <= Survival SE n Survival SE n Survival SE n Survival Age group (years) Interval (month) n >=65 Survival SE n Survival SE n Survival SE SE 177
12 PERITONEAL DIALYSIS 23rd Report of the Table (a): Unadjusted technique survival by gender (uncensored for death and transplant) Gender Interval (months) Male Female n survival SE n survival SE Figure (a): Unadjusted technique survival by gender (uncensored for death and transplant) Figure (b): Unadjusted technique survival by gender (censored for death and transplant) 1.00 Kaplan-Meier survival estimates, by sex 1.00 Kaplan-Meier survival estimates, by sex Cumulative survival Male Female Cumulative survival Male Female Duration in months Duration in months Table (b): Unadjusted technique survival by gender (censored for death and transplant) Gender Interval Male Female (months) n survival SE n survival SE
13 23rd Report of the PERITONEAL DIALYSIS Table & Figure (a) show diabe c status is ini ally associated with worse technique survival compared to non-diabe c (uncensored for death and transplant). However, when censored for death and transplant, technique survival was not different between diabe c vs non-diabe c status in the first 5 years on treatment. A er 5 years on treatment, technique survival was actually be er for pa ents with diabetes than those without (Table & Figure (b) ). Table (a): Unadjusted technique survival by diabetes status (uncensored for death and transplant), Diabetes status Interval (month ) Non-diabe c Diabe c n survival SE n survival SE Figure (a): Unadjusted technique survival by Diabetes status (uncensored for death and transplant) Kaplan-Meier survival estimates, by Diabetes Figure (b): Unadjusted technique survival by diabetes status (censored for death and transplant) Kaplan-Meier survival estimates, by Diabetes Cumulative survival Non-diabetic Cumulative survival Diabetic Non-diabetic Diabetic Duration in months Duration in months 179
14 PERITONEAL DIALYSIS 23rd Report of the Table (b): Unadjusted technique survival by diabetes status (censored for death and transplant) Diabetes status Non-diabe c Diabe c Interval (month ) n survival SE n survival SE There was no difference in technique survival between Kt/v >2.0 and Kt/V > Pa ents with Kt/V <1.7 had the worst technique survival (Table & Figure ). Table : Unadjusted technique survival by Kt/V, Kt/V Interval (months ) n < >2.0 Survival SE n Survival SE n Survival SE 180
15 23rd Report of the PERITONEAL DIALYSIS Figure : Unadjusted technique survival by Kt/V, Kaplan-Meier survival estimates, by KTV Cumulative survival Kt/V Kt/V <1.7 Kt/V > Duration in months Table shows the hazard ra o for change of dialysis modality. Factors significantly influencing change of dialysis modality were peritoni s, male gender, BMI >=25, serum albumin <30 g/dl, Hb <10.0gm/dl, serum phosphate <0.8mmol/l and Kt/V <1.7. Table : Adjusted hazard ra o for change of dialysis modality, Factors n Hazard ra o 95 CI p value Age (years) Age 1-14 (ref*) Age (0.89, 1.79) Age (0.70, 1.44) Age (0.65, 1.33) Age (0.59, 1.20) Age (0.65, 1.30) Age >= (0.61, 1.29) Peritoni s No (ref*) Yes (6.68, 8.55) <0.001 Diabetes Mellitus Non-diabe c (ref*) Diabe c (0.89, 1.19) Gender Male (ref*) Female (0.68, 0.89) <0.001 Cardiovascular Disease No CVD (ref*) CVD (0.74, 1.09) BMI < (0.84, 1.34) <25 (ref*) >= (1.27, 1.66) <
16 PERITONEAL DIALYSIS 23rd Report of the Table : Adjusted hazard ra o for change of dialysis modality, ( cont) Factors n Hazard ra o 95 CI p value Serum Albumin < (1.04, 1.44) < (0.91, 1.20) <45 (ref*) >= (0.41, 1.69) Serum cholesterol (mmol/l) < (0.84, 1.50) < (0.61, 0.85) < < (0.79, 1.14) >=6.2 (ref*) Diastolic BP < (0.77, 1.23) < (0.87, 1.18) <90 (ref*) < (1.01, 1.44) >= (0.82, 1.75) Hemoglobin (g/dl) < (1.22, 1.59) < <12 (ref*) >= (0.78, 1.27) Serum calcium (mmol/l) < (0.92, 1.22) <=2.37 (ref*) > (0.86, 1.22) Calcium Phosphate product < (0.98, 1.40) <4.5 (ref*) < (0.59, 0.98) >= (0.66, 1.41) Serum Phosphate (mmol/l) < (1.89, 6.18) < <1.3 (ref*) < (0.73, 1.03) < (0.67, 1.15) >= (0.82, 1.76) Kt/V < (1.01, 1.41) (ref*) <= (0.90, 1.20) Assisted PD Selfcare (ref*) Assisted (0.79, 1.05)
17 23rd Report of the PERITONEAL DIALYSIS Table (a) shows the reasons for PD drop out. The percentage of death (60) as a cause for PD drop-out in 2015 was compara vely low to prior 8 years. A er excluding death, peritoni s persisted as the commonest cause of technique failure over the last decade. Peritoni s contributed to 20 of PD drop-out in year 2015, followed by membrane failure (6). Table (b) shows the PD drop-out rate with me on treatment. A propor on of PD drop-out occurred before 12 months of treatment (30), while 70 occurred a er 12 months on treatment (Table b). The dura on of me spent on PD by prevalent pa ents is shown in Table A total of 709 pa ents (8.4) s ll remain on PD a er 5 years on treatment. Table (a): Reasons for drop-out from PD program, Year n n n n n n Death Transplant Peritoni s Catheter related infec on Membrane failure Technical problem Pa ent preference Others Unknown Total Year n n n n Death Transplant Peritoni s Catheter related infec on Membrane failure Technical problem Pa ent preference Others Unknown Total
18 PERITONEAL DIALYSIS 23rd Report of the Figure (a): Reasons for drop-out from PD program, Death Peritonitis Membrane failure Patient preference Unknown Transplant Catheter related infection Technical problem Others Percent () Table (b): Drop-out rate from PD program with me on treatment, Year n n n n n n < 3 months <6 months <12 months >=12 months Total Year n n n n < 3 months <6 months <12 months >=12 months Total
19 23rd Report of the PERITONEAL DIALYSIS Table : Time on PD (Prevalent PD pa ents 31 Dec 2015) 1 st Treatment (n=8459) 1 st Treatment (n=8459) Months 0-< Months SECTION 12.4: PERITONITIS The median peritoni s rate was 1 in 39.9 pa ent-months in 2015, compared to 1 in 42.9 pa entmonths in the preceding year (Table ).Inter-centre varia on remains wide from 1 episode in 19.8 pa ent-months to 1 in 96 pa ents-months (0.6 to 0.125) episodes per year at risk) in adults. Gram-posi ve organisms accounted for 35.3 of peritoni s with Staphylococcus coagulase nega ve (CoNS) as the predominant gram-posi ve organism (13.4). E. coli remained the commonest gramnega ve pathogen accoun ng for 28.4 of gram-nega ve infec ons. The fungal peritoni s rate remained rela vely unchanged at 3.9 and there was only 0.2 of mycobacterium peritoni s. The culture nega ve rate unfortunately remained high at 25.9 as compared to the ISPD target of less than 20 (Table & Figure ). For outcomes of peritoni s, it was clear that gram posi ve infec ons had be er outcomes (Table and Figure a & b). There was complete resolu on in 77.5 cases overall in the era (Table & Figure b) Gram nega ve peritoni s had higher rates of catheter removal (17.7 ) compared to gram posi ve peritoni s (10.2). The incidence of death was also higher in gram nega ve peritoni s compared to gram posi ve peritoni s, i.e versus 12.2 respec vely. Among gram nega ve infec ons, Pseudomonas and Acinetobacter have the highest incidence of deaths (30). Death rates from fungal and mycobacterial peritoni s were highest at 45 and 52 respec vely (Table & Figure b). When comparing the last 2 eras of PD i.e. and, the total mortality rate has decreased from 29.6 to Resolu on of peritoni s has improved from 53 to 58. These improvements are perhaps due to be er and earlier recogni on of peritoni s both by pa ent and staff. Catheter removal rates were similar in both eras. Total mortality rates con nue to decrease in fungal and mycobacterium peritoni s and can be explained by the ins tu on of a more aggressive approach to remove catheters. In mul variate analysis (Table ) lower income levels, age > 55 years and assistance with PD therapy appeared to contribute to an increased peritoni s risk. Diabetes was not associated with an increased risk of peritoni s. 185
20 PERITONEAL DIALYSIS 23rd Report of the Table : Varia on of peritoni s rate (pt-month/epi) among PD centres, Year Number of centres Min 5 th Cen le LQ Median UQ 95 th Cen le Max Figure (i): Varia on in peritoni s rate among adult PD centres, 2015 Figure (ii): Varia on in peritoni s rate among paediatric PD centres,
21 23rd Report of the PERITONEAL DIALYSIS Table : Causa ve organism in PD peritoni s, (A) Gram Posi ves n n n n n n n Staph. aureus Staph Coagulase Neg Strep Others (B) Gram Nega ves Pseudomonas Acinetobacter Klebsiella Enterobacter E.Coli Others (C) Polymicrobial (D) Others Fungal Mycobacterium Others (E) No growth Total (A) Gram Posi ves n n n Staph. aureus Staph Coagulase Neg Strep Others (B) Gram Nega ves Pseudomonas Acinetobacter Klebsiella Enterobacter E.Coli Others (C) Polymicrobial (D) Others Fungal Mycobacterium Others (E) No growth Total
22 PERITONEAL DIALYSIS 23rd Report of the Figure Causa ve organism in PD peritoni s, Frequency Staph. Aureus Other Gram positive E.Coli Fungal Culture Negative Staph Coagulase Neg. Pseudomonas Polymicrobial Mycobacterium Table (a): Outcome of peritoni s by causa ve organism, (A) Gram Posi ves Outcome Resolved Not resolved, catheter removed Death Total n n n n Staph. Aureus Staph Coagulase Neg Strep Others (B) Gram Nega ves Pseudomonas Acinetobacter Klebsiella Enterobacter E.Coli Others (C) Polymicrobial (D) Others Fungal Mycobacterium Others (E) No growth
23 23rd Report of the PERITONEAL DIALYSIS Table (b): Outcome of peritoni s by causa ve organism, (A) Gram Posi ves Outcome Resolved Not resolved, catheter removed Death Total n n n n Staph. Aureus Staph Coagulase Neg Strep Others (B) Gram Nega ves Pseudomonas Acinetobacter Klebsiella Enterobacter E.Coli Others (C) Polymicrobial (D) Others Fungal Mycobacterium Others (E) No growth Figure (a): Outcome of peritoni s by causave organism, 100 Resolved Not resolved, catheter removed Death Figure (b): Outcome of peritoni s by causa ve organism, 100 Resolved Not resolved, catheter removed Death Percent ( ) P ercent ( ) Staph. Aureus Staph Coagulase Neg. Strep Others Pseudomonas Acinetobacter Klebsiella Enterobacter E.Coli Others Polymicrobial Fungal Mycobacterium Others No growth 0 Staph. Aureus Staph Coagulase Neg. Strep Others Pseudomonas Acinetobacter Klebsiella Enterobacter E.Coli Others Polymicrobial Fungal Mycobacterium Others No growth 189
24 PERITONEAL DIALYSIS 23rd Report of the Figure (c): Outcome of peritoni s by causa ve organism by era, & Resolved Not resolved, catheter removed Death 100 Percent () Staph. Aureus Staph Coagulase Neg. Strep Others Pseudomonas Acinetobacter Klebsiella Enterobacter E.Coli Others Polymicrobial Fungal Mycobacterium Others No growth Outcome of peritonitis by causative organism by era Table : Risk factors influencing peritoni s rate, Factors n Risk Ra o 95 CI P value Age (years) <= (0.74, 1.08) (0.80, 1.09) (ref*) (0.90, 1.18) (0.92, 1.19) (1.06, 1.36) >= (1.09, 1.43) Gender Male (ref*) Female (0.97, 1.10) Diabetes No (ref*) Yes (0.89, 1.02) Income <RM 1000 (ref*) RM (0.76, 0.86) <0.001 RM (0.60, 0.74) <0.001 RM (0.48, 0.98) >=RM (0.27, 1.21) Educa on Nil (0.96, 1.22) 0.21 Primary (0.94, 1.09) Secondary (ref*) Ter ary (0.85, 1.07) Assistance to perform CAPD Self care (ref*) Par ally assisted (1.02, 1.22) Completely assisted (1.06, 1.25)
Chapter 12 PERITONEAL DIALYSIS
Chapter 12 PERITONEAL DIALYSIS B. Sunita A/P V. Bavanandan Anita Bhajan Manocha Lily Binti Mushahar Mohamad Zaimi Bin Abdul Wahab Sudhaharan Sivathasan PERITONEAL DIALYSIS 22nd Report of the SECTION 12.1:
More informationCHAPTER 13. Renal Transplanta on
CHAPTER 13 Renal Transplanta on Rosnawa Yahya Hooi Lai Seong Ng Kok Peng Surya Bin Yakaob Wong Hin Seng SECTION 13.1: STOCK AND FLOW The number of new transplant pa ents decreased from 151 in 26 to its
More informationCHAPTER 6 PERITONEAL DIALYSIS
CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani Hannah Dent Kylie Hurst Stephen McDonald PERITONEAL DIALYSIS ANZDATA Registry 11 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis was used to
More informationCHAPTER 6 PERITONEAL DIALYSIS. Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst Annual Report 35th Edition
CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst 212 Annual Report 35th Edition PERITONEAL DIALYSIS ANZDATA Registry 212 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya
CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal
More informationCHAPTER 5. Paediatric Renal Replacement Therapy
24th Report of the CHAPTER 5 Paediatric Renal Replacement Therapy Lee Ming Lee Lim Yam Ngo Lynster Liaw Chiew Tung Susan Pee Yap Yok Chin Wan Jazilah Wan Ismail 24th Report of the SECTION A: RRT PROVISION
More informationCHAPTER 6 PERITONEAL DIALYSIS. Neil Boudville. Hannah Dent. Stephen McDonald. Kylie Hurst. Philip Clayton Annual Report - 36th Edition
CHAPTER 6 Neil Boudville Hannah Dent Stephen McDonald Kylie Hurst Philip Clayton 213 Annual Report - 36th Edition ANZDATA Registry 213 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis was used to treat
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr (Mr) Rohan Malek Dr Wong Hin Seng Dr Fan Kin Sing Dr Rosnawati Yahya Dr S Prasad Menon Dr Tan Si
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr Zaki Morad Mohd Zaher Dato Dr (Mr) Rohan Malek Dr Fan Kin Sing Dr Lily Mushahar Dr Lim Soo Kun Dr
More informationObjectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring
Peritoneal Dialysis Prescription and Adequacy Monitoring Christine B. Sethna, MD, EdM Division Director, Pediatric Nephrology Cohen Children s Medical Center Associate Professor Hofstra Northwell School
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Rosnawati Yahya. Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng.
CHAPTER 5 Editor: Roswati Yahya Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng Contents 5. Stock and Flow of Rel Transplantation Stock and Flow Transplant Rates 5.2 Recipients
More informationChapter 5 PAEDIATRIC RENAL REPLACEMENT THERAPY. Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin
Chapter 5 PAEDIATRIC RENAL REPLACEMENT THERAPY Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin SECTION A: RRT PROVISION FOR PAEDIATRIC PATIENTS This chapter presents
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Monitoring patients on peritoneal dialysis GUIDELINES
Date written: August 2004 Final submission: July 2005 Monitoring patients on peritoneal dialysis GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationCHAPTER 14. Renal Transplantation
15th Report of the Malaysian RENAL TRANSPLANTATION CHAPTER 14 Renal Transplantation Editor: Dr. Goh Bak Leong Expert Panel: : Dato Dr. Dato Zaki Dr. Morad Zaik Morad Mohd (Chair) Zaher (Chair) Dr. Goh
More information3/21/2017. Solute Clearance and Adequacy Targets in Peritoneal Dialysis. Peritoneal Membrane. Peritoneal Membrane
3/21/2017 Solute Clearance and Adequacy Targets in Peritoneal Dialysis Steven Guest MD Director, Medical Consulting Services Baxter Healthcare Corporation Deerfield, IL, USA Peritoneal Membrane Image courtesy
More informationYou can sleep while I dialyze
You can sleep while I dialyze Nocturnal Peritoneal Dialysis Dr. Suneet Singh Medical Director, PD, VGH Division of Nephrology University of British Columbia Acknowledgements Melissa Etheridge You can sleep
More informationAna Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More informationChapter 7: Adequacy of Haemodialysis and Serum Bicarbonate
Chapter 7: Adequacy of Haemodialysis and Serum Bicarbonate Summary. The urea reduction ratio (URR) has been rising year on year but now appears to have reached a plateau.. The URR increases the longer
More informationPD In Acute Kidney Injury. February 7 th -9 th, 2013
PD In Acute Kidney Injury February 7 th -9 th, 2013 Objectives PD as a viable initial therapy PD in AKI PD versus dhd PD versus CVVHD Why not PD first PD for AKI Early days (1970 s) PD was the option of
More informationImad Ahmed MD. Renal Associates of West Michigan
Imad Ahmed MD Renal Associates of West Michigan ESRD Facts: - Medicare funded program - Cost - Significant mortality and morbidity - Reduced quality of life - Shrinking donor pool ESRD CAUSES - DM - Hypertension
More informationKIDNEY DIALYSIS FOUNDATION ANNUAL REPORT PERITONEAL DIALYSIS PROGRAMME
KIDNEY DIALYSIS FOUNDATION ANNUAL REPORT PERITONEAL DIALYSIS PROGRAMME 2011 Prepared by Dr Grace Medical Director With input from: Lay Kwee Chin Senior Nurse Clinician, Patient Services Theresa Soh Clinical
More informationPERITONEAL EQUILIBRATION TEST. AR. Merrikhi. MD. Isfahan University of Medical Sciences
PERITONEAL EQUILIBRATION TEST AR. Merrikhi. MD. Isfahan University of Medical Sciences INTRODUCTION The peritoneal equilibration test (PET) is a semiquantitative assessment of peritoneal membrane transport
More informationPERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT GUIDE
PERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT GUIDE TABLE OF CONTENTS Introduction.... 3 SECTION 1: FUNDAMENTALS OF THE PRESCRIPTION.... 4 Getting Started: Patient Pathway to First Prescription.... 5 Volume
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationMicrobiology Risk Factors and Outcomes of Peritonitis in Tunisian Peritoneal Dialysis Patients
Original Article World J Nephrol Urol. 2018;7(2):45-52 Microbiology Risk Factors and Outcomes of Peritonitis in Tunisian Peritoneal Dialysis Patients Lilia Ben Lasfar a, b, Yosra Guedri a, Awatef Azzebi
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationmorbidity & mortality
morbidity & mortality esrd introduction of ESRD treatment. We examine these concerns throughout the ADR, particularly in Chapter One. This year we focus on infectious complications, especially those related
More informationSmart APD prescription. Prof. Wai Kei Lo Tung Wah Hospital The University of Hong Kong
Smart APD prescription Prof. Wai Kei Lo Tung Wah Hospital The University of Hong Kong Costing Comparison of Different Modes of RRT in Hong Kong in 2011 (Per Year) HK$300,000 HK$250,000 HK$200,000 HK$150,000
More informationCHAPTER 5 RENAL TRANSPLANTATION
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr. Goh Bak Leong Expert Panel: Dato Dr. Zaki Morad b Mohd Zaher (Chair) Dr. Goh Bak Leong (Co-Chair) Dr. Fan Kin Sing Dr. Lily Mushahar Mr. Rohan Malek Dr. S. Prasad
More informationReinitiation of peritoneal dialysis after catheter removal for refractory peritonitis
J Nephrol (2014) 27:445 449 DOI 10.1007/s40620-014-0048-1 ORIGINAL ARTICLE Reinitiation of peritoneal dialysis after catheter removal for refractory peritonitis R. Ram G. Swarnalatha K. V. Dakshinamurty
More informationChapter 12. End Stage Kidney Disease in Indigenous Peoples of Australia and Aotearoa/New Zealand. ANZDATA Registry 39th Annual Report
Chapter 12 End Stage Kidney Disease in Indigenous Peoples of and Aotearoa/ 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, the rates and practice patterns for end-stage
More informationChapter 2 Peritoneal Equilibration Testing and Application
Chapter 2 Peritoneal Equilibration Testing and Application Francisco J. Cano Case Presentation FW, a recently diagnosed patient with CKD Stage 5, is a 6-year-old boy who has been recommended to initiate
More informationFistula First? Vascular Symposium 4/28/18
Fistula First? Vascular Symposium 4/28/18 Disclosure I have no financial interest to disclose connected to any of the information presented in this discussion Objectives Scope of Problem Benefits of PD
More informationPERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS
More informationPrincess Alexandra Hospital, Brisbane
Princess Alexandra Hospital Coagulase Negative Staphylococcal Peritonitis in Australian Peritoneal Dialysis Patients Predictors, Treatment and Outcomes in 936 cases Dr Magid Fahim Princess Alexandra Hospital,
More informationKIDNEY DIALYSIS FOUNDATION ANNUAL REPORT MEDICAL (P.D.)
KIDNEY DIALYSIS FOUNDATION ANNUAL REPORT MEDICAL (P.D.) 2005 Prepared by Dr Grace Lee Medical Director With input from: Theresa Soh Manager, Patient Services Wu Sin Yan Charge Nurse TABLE OF CONTENTS 1.
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 22, 2006 Costas Fourtounas, Eirini Savidaki, Marilena Roumelioti, Periklis Dousdampanis, Andreas Hardalias, Pantelitsa Kalliakmani,
More informationPD prescribing for all. QUESTION: Which approach? One size fits all or haute couture? (1) or (2)? The patient 18/03/2014.
PD prescribing for all Pr Max Dratwa Honorary consultant, Nephrology-Dialysis CHU Brugmann Université Libre de Bruxelles BSN 22 March 2014 QUESTION: Which approach? One size fits all or haute couture?
More informationSupplemental data to article. Association of ESA hypo-responsiveness and haemoglobin variability with. mortality in hemodialysis patients
Supplemental data to article Association of ESA hypo-responsiveness and haemoglobin variability with mortality in hemodialysis patients A. Kainz, B. Mayer, R. Kramar, R. Oberbauer Table of Contents Hb
More informationKrediet slide di 18
1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision
More informationFrom Peritoneal Dialysis to Hemodialysis How could we improve the transition? Th Lobbedez CHU de Caen Self Dialysis Meeting 22 May 2014
From Peritoneal Dialysis to Hemodialysis How could we improve the transition? Th Lobbedez CHU de Caen Self Dialysis Meeting 22 May 2014 Deux grands principes concernant la DP La dialyse péritonéale doit
More informationAJNT. Original Article
. 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationOriginal Articles. Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis
Nephrol Dial Transplant (2014) 29: 1940 1947 doi: 10.1093/ndt/gfu050 Advance Access publication 3 March 2014 Original Articles Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis
More informationCHAPTER 12 END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND. Stephen McDonald. Matthew Jose. Kylie Hurst INDIGENOUS 12-1
ANZDATA Registry 213 Report INDIGENOUS END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND CHAPTER 12 Stephen McDonald Matthew Jose Kylie Hurst 213 Annual Report - 36th Edition
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationIncreased peritoneal dialysis utilization and improved patient survival over a 20-year period: data from a Portuguese Peritoneal Dialysis Unit
ORIGINAL ARTICLE Port J Nephrol Hypert 2016; 30(2): 113-120 Advance Access publication 30 January 2016 Increased peritoneal dialysis utilization and improved patient survival over a 20-year period: data
More informationDialysis, personalized. More options for your patients well being.
Dialysis, personalized. More options for your patients well being. Discover the advanced peritoneal dialysis (PD) system with improved features for added control and convenience during your patients treatment
More informationUpdate in Peritoneal dialysis
Update in Peritoneal dialysis Matthew Jose MBBS, FRACP, PhD, FASN, AFRACMA Royal Hobart Hospital FACULTY OF HEALTH I pay my respects to the traditional owners of this land, the Larrakia people, and to
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationHyperphosphatemia is a strong predictor of overall
Peritoneal Phosphate Clearance is Influenced by Peritoneal Dialysis Modality, Independent of Peritoneal Transport Characteristics Sunil V. Badve,* Deborah L. Zimmerman,* Greg A. Knoll, * Kevin D. Burns,*
More informationA clinical audit to compare peritonitis rates between peritoneal dialysis delivery systems
A clinical audit to compare peritonitis rates between peritoneal dialysis delivery systems Lesley Williams, Clint Douglas, Ann Bonner, Nicola Williams & Dwarakanathan Ranganathan Submitted: 19 December
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationYeatsh CHAPTER. William Butler
Sickness brought me this Thought, in that scale his: Why should I be dismayed Though Lame had burned the whole World, as it were a coal, Now I have seen it weighed Against a soul? William Butler Yeatsh
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationPeritonitis is a major cause of morbidity and mortality
Proceedings of the First Asian Chapter Meeting ISPD December 13 15, 2002, Hong Kong Peritoneal Dialysis International, Vol. 23 (2003), Supplement 2 0896-8608/03 $3.00 +.00 Copyright 2003 International
More informationNational Surveillance System for Dialysis Centre and Dialysis Associated Diseases
National Surveillance System for Dialysis Centre and Dialysis Associated Diseases Dr Richard Fluck Consultant Renal Physician & Clinical Director, Royal Derby Hospital UK RA Vascular Access Survey 2005
More information. Time to transplant listing is dependent on. . In 2003, 9.1% of all prevalent transplant. . Patients with diabetes mellitus are less
Chapter 5: Joint Analyses with UK Transplant in England and Wales; Access to the Renal Transplant Waiting List, Time to Listing, Diabetic Access to Transplantation and the Influence of Social Deprivation
More informationPERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT QUICK REFERENCE GUIDE
PERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT QUICK REFERENCE GUIDE This quick reference guide will help serve as a reference tool for clinicians setting a patient s Peritoneal Dialysis (PD) prescription.
More informationDialysis: the long case
Dialysis: the long case Prof Mark Brown St George Public Hospital, Kogarah The case SD 1. What significant things have been omitted from the history? 2. Physical findings 70 RTA; mitral regurg murmur;
More informationOptions in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology
Options in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology CKD Classification Stage Description GFR (ml/min/1.73.m2) 1 Kidney
More informationChapter 2. Prevalence of End Stage Kidney Disease. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter 2 Prevalence of End Stage Kidney Disease 2016 ANZDATA Registry 39th Annual Report Data to 31-Dec-2015 Renal Replacement Therapy Table 2.1 shows the prevalence (pmp) of renal replacement therapy
More informationFULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access
INTRODUCTION ANEMIA TREATMENT hemoglobin levels epo treatment iron treatment FULFILLMENT OF K/DOQI GUIDELINES 2 anemia treatment dialysis therapy vascular access EPO DOSING PATTERNS 4 epo dosing per kg
More informationRenal Association Clinical Practice Guideline on peritoneal dialysis in adults and children
Woodrow et al. BMC Nephrology (2017) 18:333 DOI 10.1186/s12882-017-0687-2 CORRESPONDENCE Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children Graham Woodrow 1*, Stanley
More informationVolume Management 2/25/2017. Disclosures statement: Objectives. To discuss evaluation of hypervolemia in peritoneal dialysis patients
Volume Management Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 14, 2017 Disclosures statement: Consultant: Allena, Becker Professional Education Grant
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationUnited States Renal Data System (USRDS) International Data Collection Form
United States Renal Data System (USRDS) International Data Collection Form This form is designed to solicit information on the population of End-Stage Renal Disease (ESRD) patients in your country who
More informationOxford Kidney Unit What do my blood and dialysis results mean? Information for patients
Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients page 2 If you are on haemodialysis (HD) or peritoneal dialysis (PD) this leaflet is for you. It will provide you
More informationOUTCOME FOLLOWING CAPD-ASSOCIATED GRAM-NEGATIVE PERITONITIS
66 OUTCOME FOLLOWING CAPD-ASSOCIATED GRAM-NEGATIVE PERITONITIS CHIA-SHENG CHEN, SHYI-YU CHUNG, WEN-LIANG YU*, MING-TZUNG KAO Peritonitis remains the leading cause of patient dropout from peritoneal dialysis
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2001
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2001 [Before completing please read instructions at the bottom of this page and on pages 4 and 5] PATIENT IDENTIFICATION MAKE
More informationCHAPTER 2. Prevalence of Renal Replacement Therapy for End Stage Kidney Disease
CHAPTER 2 Prevalence of Renal Replacement Therapy for End Stage Kidney Disease Summarising the number of prevalent renal replacement therapy patients in Australia and New Zealand, the prevalence rate per
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More information3/5/18. Background. Registry Reports. Dialysis Registry Update and Future Directions
Dialysis Registry Update and Future Directions Annabelle N. Chua, MD March 4, 2018 Background Founded in 1987 as a transplant registry Expanded registry to include dialysis (1992) and CKD (1994) Patient
More informationPeriodic Peritoneal Dialysis in End Stage Renal Disease: Is it Still Relevant? A Single Center Study from India
Original Article Periodic Peritoneal Dialysis in End Stage Renal Disease: Is it Still Relevant? A Single Center Study from India Gandhi K, Prasad D, Malhotra V, Agrawal D, Beniwal P, Mathur M Department
More informationMETABOLISM AND NUTRITION WITH PD OBESITY. Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle
METABOLISM AND NUTRITION WITH PD OBESITY Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle 1 Body Size in Patients New to Dialysis United States Body Mass Index, kg/m2 33 31
More informationCHAPTER 5. Haemodialysis. Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald
CHAPTER Haemodialysis Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald STOCK AND FLOW AUSTRALIA The annual stock and flow of HD patients during the period - is shown in Figures.,.
More informationad e quate adjective \ˈa-di-kwət\
PD Prescriptions and Adequacy Monitoring: The Basics Fundamentals of Dialysis in Children Seattle, Washington February 27th, 2016 Colin White Steve Alexander Brad Warady Alicia Neu Franz Schaefer Bruce
More informationTHERAPEUTIC INTERVENTIONS TO PRESERVE RESIDUAL KIDNEY FUNCTION. Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle
THERAPEUTIC INTERVENTIONS TO PRESERVE RESIDUAL KIDNEY FUNCTION Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle 1 2 Outline of Presentation Refinements in our understanding
More informationPichaya Tantiyavarong, 1,2 Opas Traitanon, 2 Piyatida Chuengsaman, 3 Jayanton Patumanond, 1 and Adis Tasanarong Introduction
International Nephrology Volume 2016, Article ID 6217135, 8 pages http://dx.doi.org/10.1155/2016/6217135 Research Article Dialysate White Blood Cell Change after Initial Antibiotic Treatment Represented
More informationNew Zealand. Dialysis and Transplantation Audit
New Zealand Dialysis and Transplantation Audit Report for New Zealand Nephrology Services on behalf of the National Renal Advisory Board Grant Pidgeon Standards and Audit Subcommittee July 2012 Establishment
More informationThe role of automated peritoneal dialysis (APD) in an integrated dialysis programme
The role of automated peritoneal dialysis (APD) in an integrated dialysis programme Paul Williams*^, Linda Cartmel* and Jane Hollis^ *CAPD Unit, Ipswich Hospital, Ipswich, UK; 1CAPD Unit, Addenbrooke's
More informationPEACEHEALTH LABORATORIES
360-414-2306 www.peacehealthlabs.org Critical Values Call List - Longview Critical values are reported per the criteria published below. Laboratory results meeting these criteria indicate potential life-threatening
More informationPredictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran
Dialysis Predictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran Monir Sadat Hakemi, 1 Mehdi Golbabaei, 2 Amirahmad Nassiri, 3 Mandana
More informationDrug Use in Dialysis
(Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS
More informationState Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE
Dear State Surveyor: State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE This report is designed to provide a comparative summary of treatment patterns and patient outcomes for
More informationTop Papers in Cri-cal Care Janna Landsperger, ACNP- BC
Top Papers in Cri-cal Care 2016 Janna Landsperger, ACNP- BC Objec-ves Review journal articles regarding delivery of critical care published over the past twelve months Provide evidence in support of current
More informationGambrosol Trio, clinical studies 91 Glitazone, malnutrition-inflammationatherosclerosis
Subject Index Acidosis, see Metabolic acidosis Activated carbon, sorbents 337 Adipokines adipose tissue and systemic inflammation 169 functions 167 169 prospects for study in renal patients 171 Adiponectin,
More informationEnd Stage Kidney Disease Among Indigenous Peoples of Australia and New Zealand
Chapter 12 End Stage Kidney Disease Among Indigenous Peoples of and New Zealand 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, rates of end-stage kidney disease
More informationPatients with underlying liver disease and ascites are
Peritoneal Dialysis International, Vol. 26, pp. 213 217 Printed in Canada. All rights reserved. 0896-8608/06 $3.00 +.00 Copyright 2006 International Society for Peritoneal Dialysis CONTINUOUS AMBULATORY
More informationANNUAL REPORT The Norwegian Renal Registry. (Norsk Nefrologiregister)
ANNUAL REPORT 21 The Norwegian Renal Registry (Norsk Nefrologiregister) This report will also be available on: http://152.94.12.23/nyreforening/uremiregisteret/esdr.html Correspondence to: Overlege dr.med
More informationPeritoneal Dialysis Prescriptions: A Primer for Nurses
Peritoneal Dialysis Prescriptions: A Primer for Nurses A Primer ABCs of PD R x Betty Kelman RN-EC MEd CNeph (C) Toronto General Hospital University Health Network Toronto, Ontario, Canada A moment to remember
More informationOverall: about 257,000 (23%) Saskatchewan residents had at least one of five chronic diseases: asthma,
P r e v a l e n c e o f A s t h m a, C O P D, D i a b e t e s, I s c h e m i c H e a r t D i s e a s e a n d H e a r t Fa i l u r e i n S a s k a t c h e w a n 2 1 2 / 1 3 R e p o r t r e l e a s e d a
More informationKnow The Facts About Home Dialysis Choices
Know The Facts About Home Dialysis Choices Fact Sheet www.esrdncc.org Table of Contents What are my choices for dialysis at home?...3 Why consider home hemodialysis?...4 What are the different types of
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Mode of dialysis at initiation GUIDELINES
Date written: September 2004 Final submission: February 2005 Mode of dialysis at initiation GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationClinical Study Results in Assisted Peritoneal Dialysis: A Ten-Year Experience
International Nephrology Volume 2015, Article ID 712539, 5 pages http://dx.doi.org/10.1155/2015/712539 Clinical Study Results in Assisted Peritoneal Dialysis: A Ten-Year Experience Sara Querido, 1 Patrícia
More informationDialysis outcomes: can we do better?
Dialysis outcomes: can we do better? Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director, Chronic Disease Research Group Minneapolis Medical Research Foundation Director,
More informationCHAPTER 4 METHOD AND LOCATION OF DIALYSIS. Nancy Briggs Kylie Hurst Stephen McDonald Annual Report 35th Edition
CHAPTER 4 METHOD AND LOCATION OF DIALYSIS Nancy Briggs Kylie Hurst Stephen McDonald 212 Annual Report 35th Edition METHOD AND LOCATION OF DIALYSIS ANZDATA Registry 212 Report AUSTRALIA Figure 4.1 Aust
More informationHAEMODIALYSIS GOVERNMENT CENTRES
HAEMODIALYSIS IN GOVERNMENT CENTRES Stock and Flow Place of Haemodialysis and its Finance Death on Haemodialysis and Transfer to PD Government Haemodialysis Centres Haemodialysis Patient Characteristics
More informationPREDICTORS OF PERITONITIS AMONG CANADIAN PERITONEAL DIALYSIS PATIENTS
PREDICTORS OF PERITONITIS AMONG CANADIAN PERITONEAL DIALYSIS PATIENTS By Sharon J. Nessim, MD A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department
More information